Representative · D-NJ
The bill increases protection of classified and mission‑critical work by expanding standardized drug testing for sensitive federal employees, but does so at the cost of employee job risk and privacy/due‑process concerns and with added administrative expense.
Federal employees in sensitive (SGE) roles will be less likely to be drug-impaired on the job, reducing risks to national security and mission safety and helping maintain public trust in protection of classified and mission‑critical duties.
Federal agencies gain a single, legally referenced testing standard (the Mandatory Guidelines) that simplifies and standardizes how drug testing is implemented across the government.
Federal SGEs who test positive face loss of employment and a 12-month ineligibility period, which can be economically severe for individuals (including those with substance‑use disorders) and their families.
Broad/random testing of SGEs raises privacy and due‑process concerns for federal employees, including the risk of false positives and reputational harm.
Implementing random testing across many SGEs will create administrative and program costs for agencies and taxpayers and may divert resources from other priorities.
Based on analysis of 2 sections of legislative text.
Requires pre-appointment and random drug testing for special Government employees in sensitive positions and bars/ removes those who test positive for at least 12 months.
Official title: To require drug testing for special Government employees, and for other purposes.
Introduced April 1, 2025 by Mikie Sherrill · Last progress April 1, 2025
Requires federal agencies to drug-test special Government employees (SGEs) who occupy sensitive positions. Agencies must administer a pre-appointment drug test under the federal Mandatory Guidelines before an SGE’s first day of service, enroll current SGEs in sensitive roles into a random drug-testing program within 90 days of enactment, and remove or bar individuals who test positive for at least 12 months.